SMTL ID : 7r7r.1

Structure of Human Anaplastic Lymphoma Kinase Domain in complex with ((2~{R})-2-[5-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]-4-methyl-thiazol-2-yl]propane-1,2-diol)

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.94 Å

Oligo State

monomer

Ligands

1 x AWJ: (2R)-2-[5-(6-amino-5-{(1R)-1-[2-(1,3-dihydro-2H-1,2,3-triazol-2-yl)-5-fluorophenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol(Non-covalent)

AWJ.1: 17 residues within 4Å: Chain A: L.38, G.39, H.40, V.46, A.64, L.112, E.113, L.114, M.115, G.118, D.119, S.122, R.169, N.170, L.172, G.185, D.186 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:L.38, A:L.38, A:V.46, A:L.172, A:L.172 Hydrogen bonds: A:E.113, A:M.115, A:D.119, A:D.119, A:S.122 Water bridges: A:D.119 Halogen bonds: A:N.170

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Shiba-Ishii, A. et al., Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer (2022)

Release Date

2022-06-29

Peptides

ALK tyrosine kinase receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

ALK tyrosine kinase receptor

Related Entries With Identical Sequence